Cite
HARVARD Citation
Makker, V. et al. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet oncology. 20 (5), pp. 711-718. [Online].